+86-13524779951 sales@x-mobio.com
产品类别
  原料药
  抗癌类
  抗血栓类
  丙肝类
  风湿类
  糖尿病类
  神经系统类
  其他
  中间体
  特色产品
  其他

产品介绍
产品描述
Palbociclib, also known as PD-0332991, is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. Palbociclib, was approved on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor-positive advanced breast cancer. 
化学结构
 
化学名称
6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 
SMILES Code
O=C1C(C(C)=O)=C(C)C2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C5CCCC5 
基本信息
产品编号:XM703 
产品名称:Palbociclib free base 
别名:PD-0332991; PD 0332991; PD0332991; Palbociclib free base, brand name: Ibrance. 
CAS#:571190-30-2 (free base) 
分子式:C24H29N7O2 
精确分子量:447.23827 
分子量:447.543 
纯度:>98% 
物化性质



该产品只供科研使用,不能给病人提供。

电话: +8613524779951  QQ: 点击这里给我发消息
Email: sales@x-mobio.com   Web: www.x-mobio.com  沪ICP备17047952号-1
版权所有© 2017 上海兴默生物技术有限公司     技术支持:华夏化工网 后台管理  企业邮箱